PE20240913A1 - Anticuerpos anti-il-2r agonistas y metodos de uso - Google Patents

Anticuerpos anti-il-2r agonistas y metodos de uso

Info

Publication number
PE20240913A1
PE20240913A1 PE2023002728A PE2023002728A PE20240913A1 PE 20240913 A1 PE20240913 A1 PE 20240913A1 PE 2023002728 A PE2023002728 A PE 2023002728A PE 2023002728 A PE2023002728 A PE 2023002728A PE 20240913 A1 PE20240913 A1 PE 20240913A1
Authority
PE
Peru
Prior art keywords
seq
il2r
methods
antibodies
fewer substitutions
Prior art date
Application number
PE2023002728A
Other languages
English (en)
Spanish (es)
Inventor
Nathan Trinklein
Katherine Harris
Kyle Lorentsen
Chaudhry Harbani Kaur Malik
Kaitlyn Loughlin
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of PE20240913A1 publication Critical patent/PE20240913A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PE2023002728A 2021-04-02 2022-04-01 Anticuerpos anti-il-2r agonistas y metodos de uso PE20240913A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163170383P 2021-04-02 2021-04-02
US202163239883P 2021-09-01 2021-09-01
PCT/US2022/023058 WO2022212848A1 (en) 2021-04-02 2022-04-01 Agonistic anti-il-2r antibodies and methods of use

Publications (1)

Publication Number Publication Date
PE20240913A1 true PE20240913A1 (es) 2024-04-30

Family

ID=81385128

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002728A PE20240913A1 (es) 2021-04-02 2022-04-01 Anticuerpos anti-il-2r agonistas y metodos de uso

Country Status (18)

Country Link
US (3) US11884735B2 (cg-RX-API-DMAC7.html)
EP (1) EP4314067A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024512982A (cg-RX-API-DMAC7.html)
KR (1) KR20230165263A (cg-RX-API-DMAC7.html)
AU (1) AU2022252398A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020219A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214587A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023002895A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023014054A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230507A (cg-RX-API-DMAC7.html)
IL (1) IL305944A (cg-RX-API-DMAC7.html)
JO (1) JOP20230234A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023011624A (cg-RX-API-DMAC7.html)
PE (1) PE20240913A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023552763A1 (cg-RX-API-DMAC7.html)
TW (1) TW202304994A (cg-RX-API-DMAC7.html)
UY (1) UY39715A (cg-RX-API-DMAC7.html)
WO (1) WO2022212848A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
TW202304994A (zh) * 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗il-2r抗體及使用方法
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
TW202602940A (zh) 2024-04-09 2026-01-16 美商安進公司 激動性抗il-2rbg重鏈抗體
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2026033139A1 (en) 2024-08-09 2026-02-12 Twain Therapeutics Pte. Ltd. Antigen-binding molecules

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトIL−2レセプターγ鎖分子
WO1996021732A1 (en) 1995-01-09 1996-07-18 Boehringer Ingelheim International Gmbh Il-2r-associated polypeptide and dna molecules coding therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
AU2937597A (en) 1996-05-10 1997-12-05 Biogen, Inc. Common gamma chain blocking agents
US6103879A (en) 1996-06-21 2000-08-15 Axys Pharmaceuticals, Inc. Bivalent molecules that form an activating complex with an erythropoietin receptor
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
JP2006505546A (ja) 2002-10-10 2006-02-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 二重特異性抗ErbB抗体および腫瘍治療でのその使用
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP1776383B1 (en) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EP2560994B1 (en) 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
RU2693078C2 (ru) 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US10239951B2 (en) 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
PT3328894T (pt) * 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
CN111954680B (zh) 2017-11-10 2024-03-15 新加坡科技研究局 IL2Rβ/共同γ链抗体
WO2020094836A1 (en) * 2018-11-09 2020-05-14 Euchloe Bio Pte. Ltd. Il2rbeta/common gamma chain antibodies
WO2020094834A1 (en) * 2018-11-09 2020-05-14 Euchloe Bio Pte. Ltd. Il2rbeta/common gamma chain antibodies
CN113474370B (zh) 2019-02-01 2025-04-01 瑞泽恩制药公司 抗IL2受体γ抗原结合蛋白
TW202304994A (zh) * 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗il-2r抗體及使用方法

Also Published As

Publication number Publication date
CR20230507A (es) 2023-12-12
MX2023011624A (es) 2023-10-11
CA3214587A1 (en) 2022-10-06
US20240018250A1 (en) 2024-01-18
KR20230165263A (ko) 2023-12-05
JOP20230234A1 (ar) 2023-09-26
US12590163B2 (en) 2026-03-31
US11884735B2 (en) 2024-01-30
CL2025001688A1 (es) 2025-08-18
IL305944A (en) 2023-11-01
US20230242653A1 (en) 2023-08-03
CL2023002895A1 (es) 2024-02-02
TW202304994A (zh) 2023-02-01
BR112023020219A2 (pt) 2024-02-06
CO2023014054A2 (es) 2023-11-10
AU2022252398A9 (en) 2024-01-11
WO2022212848A1 (en) 2022-10-06
US20260176366A1 (en) 2026-06-25
AU2022252398A1 (en) 2023-09-21
UY39715A (es) 2022-10-31
PH12023552763A1 (en) 2024-04-15
JP2024512982A (ja) 2024-03-21
EP4314067A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
CL2025001688A1 (es) Anticuerpo de cadena pesada anti-il2rb/il2rg; composición farmacéutica; y su uso.
CL2021003196A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 (divisional de solicitud n° 201902850)
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
ECSP19078502A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
BR112022002837A2 (pt) Anticorpo anti-vd1 ou fragmento do mesmo, anticorpo multiespecífico isolado ou fragmento do mesmo, anticorpo humano e anticorpo multiespecífico isolado humano ou fragmento do mesmo
PE20170912A1 (es) Conjugados de anticuerpo-farmaco
PE20241349A1 (es) Anticuerpos de union a cd3
EA202091747A1 (ru) Составы антитела b7-h4
PE20131209A1 (es) Anticuerpos anti-fap
MX2022005221A (es) Conjugados de anticuerpo y farmaco de eribulina anti-mesotelina y metodos de uso.
PE20191487A1 (es) Anticuerpos anti-gitr y metodos de uso de los mismos
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
JOP20220357A1 (ar) ربط أجسام مضادة متعددة الخصوصية مع bcma
EA201100779A1 (ru) Композиции антител к cxcr1 и способы их применения
PE20091655A1 (es) Farmaco para el cancer de higado
PE20211296A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
AR084315A1 (es) Anticuerpos anti-notch1
EA202193309A1 (ru) Конъюгаты антитело к тканевому фактору-лекарственное средство и связанные способы
JOP20230109A1 (ar) أجسام مضادة ثقيلة السلسلة ترتبط مع مستقبل ألفا فولات
PE20121494A1 (es) Anticuerpos anti notch-1
PE20241584A1 (es) Proteinas que se unen a nkg2d, cd16 y baff-r
MX2020010653A (es) Anticuerpo anti-muerte programada-ligando 1 y su uso.